사자발쑥 추출물을 포함하는 약학 조성물
    1.
    发明公开
    사자발쑥 추출물을 포함하는 약학 조성물 有权
    含有ARTEMISIA PRINCEPS的药物组合物

    公开(公告)号:KR1020090064697A

    公开(公告)日:2009-06-22

    申请号:KR1020070131988

    申请日:2007-12-17

    Applicant: 강화군

    Abstract: A pharmaceutical composition containing an Artemisia princeps is provided to induce apoptosis of cells of ovarian cancer and leukemia and suppress the activation of cholesterol acyltransferase. A pharmaceutical composition for preventing and treating cancer comprises (3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide) as an active ingredient. The (3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide) is isolated from an Artemisia princeps and contained in a ratio of 0.01-99 weight%. The cancer is ovarian cancer and leukemia. A pharmaceutical composition for preventing and treating cardiac circulation diseases comprises the (3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide) as an active ingredient. The cardiac circulation diseases are hyperlipidemia, coronary heart disease, arteriosclerosis or myocardial infarction.

    Abstract translation: 提供含有青蒿的药物组合物以诱导卵巢癌和白血病细胞的凋亡并抑制胆固醇酰基转移酶的活化。 用于预防和治疗癌症的药物组合物包含作为活性成分的(3-(2-甲基 - 丁酰氧基)-costu-1(10),4(5) - 二 - 12,6-二醇)。 (3-(2-甲基 - 丁酰氧基)-costu-1(10),4(5)-ien-12,6-olide)从艾蒿中分离,其含量为0.01-99重量%。 癌症是卵巢癌和白血病。 用于预防和治疗心脏循环疾病的药物组合物包含作为活性成分的(3-(2-甲基 - 丁酰氧基)-costu-1(10),4(5)-ien-12,6-olide)。 心脏循环疾病是高脂血症,冠心病,动脉硬化或心肌梗死。

    사자발쑥 추출물을 포함하는 약학 조성물
    2.
    发明授权
    사자발쑥 추출물을 포함하는 약학 조성물 有权
    可以帮助学习者更好地学习

    公开(公告)号:KR100933738B1

    公开(公告)日:2009-12-24

    申请号:KR1020070131988

    申请日:2007-12-17

    Applicant: 강화군

    Abstract: 본 발명은 사자발쑥 추출물을 포함하는 약학 조성물에 관한 것으로, 특히 사자발쑥으로부터 추출한 3-(2-메틸-부티릴옥시)-코스투-1(10),4(5)-디엔-12,6-올라이드(3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide)를 유효성분으로 포함하여 암 질환 뿐 아니라 심장순환계 질환의 예방 및 치료에 효과적인 약학 조성물에 관한 것이다.
    3-(2-메틸-부티릴옥시)-코스투-1(10),4(5)-디엔-12,6-올라이드, 사자발쑥, 난소암, 백혈병, 심장순환계 질환

    Abstract translation: 提供含有艾蒿的药物组合物以诱导卵巢癌和白血病细胞的凋亡并抑制胆固醇酰基转移酶的活化。 用于预防和治疗癌症的药物组合物包含作为活性成分的(3-(2-甲基丁酰氧基) - 缩水甘油-1(10),4(5) - 二烯-12,6-内酯)。 从蒿属植物中分离出(3-(2-甲基丁酰氧基) - 羰基-1(10),4(5) - 二烯-12,6-内酯),其含量为0.01-99重量%。 癌症是卵巢癌和白血病。 用于预防和治疗心脏循环疾病的药物组合物包含作为活性成分的(3-(2-甲基丁酰氧基) - 缩水甘油-1(10),4(5) - 二烯-12,6-内酯)。 心脏循环疾病是高脂血症,冠心病,动脉硬化或心肌梗塞。

    신규한 세스퀴테르펜 화합물
    3.
    发明授权
    신규한 세스퀴테르펜 화합물 有权
    신규한세스퀴테르펜화합물

    公开(公告)号:KR100929098B1

    公开(公告)日:2009-11-30

    申请号:KR1020090069668

    申请日:2009-07-29

    Applicant: 강화군

    Abstract: 본 발명은 사자발쑥 추출물에 관한 것으로, 특히 사자발쑥으로부터 추출한 3-(2-메틸-부티릴옥시)-코스투-1(10),4(5)-디엔-12,6-올라이드(3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide)에 관한 것이다.
    3-(2-메틸-부티릴옥시)-코스투-1(10),4(5)-디엔-12,6-올라이드, 사자발쑥, 난소암, 백혈병, 심장순환계 질환

    Abstract translation: 提供含有从提取物中分离的艾蒿提取物或倍半萜烯化合物的药物组合物具有强烈的细胞毒性,例如抑制癌细胞增殖或诱导细胞凋亡。 用于治疗癌症或心脏循环系统疾病的药物组合物包含从提取物中分离的化学式1的艾蒿提取物或倍半萜烯化合物。 化学式1的倍半萜烯化合物是3-(2-甲基丁酰氧基) - 羰基-1(10),4(5) - 二烯-12,6-内酯。 生产化学式1的倍半萜化合物的方法包括:将干燥的蒿属植物在C1-C4的低级醇中浸渍24小时的步骤; 以及过滤,压缩和分离的步骤。

    신규한 세스퀴테르펜 화합물
    4.
    发明公开
    신규한 세스퀴테르펜 화합물 有权
    新型复合化合物

    公开(公告)号:KR1020090086506A

    公开(公告)日:2009-08-13

    申请号:KR1020090069668

    申请日:2009-07-29

    Applicant: 강화군

    Abstract: A pharmaceutical composition containing Artemisia princeps PAMPANINI extract or sesquiterpene compound isolated from the extract is provided to have strong cytotoxicity such as suppression of cancer cell proliferation or induction of apoptosis. A pharmaceutical composition for treating cancer or heart circulatory diseases comprises Artemisia princeps PAMPANINI extract or sesquiterpene compound of the chemical formula 1 isolated from the extract. The sesquiterpene compound of the chemical formula 1 is 3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide. A method for producing the sesquiterpene compound of the chemical formula 1 comprises: a step of dipping dried Artemisia princeps in low alcohol of C1-C4 for 24 hours; and a step of filtering, compressing and fractioning.

    Abstract translation: 提供含有从提取物中分离的青蒿提取物或倍半萜烯化合物的药物组合物以具有强的细胞毒性,例如抑制癌细胞增殖或诱导细胞凋亡。 用于治疗癌症或心脏循环系统疾病的药物组合物包括从提取物中分离的化学式1的青蒿提取物或倍半萜烯化合物。 化学式1的倍半萜化合物是3-(2-甲基 - 丁酰氧基) - 硬脂酸-1(10),4(5) - 二 - 12,6-二醇。 制备化学式1的倍半萜烯化合物的方法包括:将干燥的青蒿干燥在C1-C4的低醇中浸渍24小时的步骤; 以及过滤,压缩和分馏的步骤。

Patent Agency Ranking